Factors associated with long-term oral hypoglycemic agent responsiveness in Korean patients with type 2 diabetes mellitus

Diabetes and Metabolism Journal

Volumn 35, Issue 3, 2011, Pages 282-289

  Kim, Bo Yeon ^a   Jung, Chan Hee ^a   Mok, Ji Oh ^a   Kim, Chul Hee ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

C peptide; Diabetes mellitus; Oral hypoglycemic agent responsiveness; Type 2

Indexed keywords

EID: 84864827368     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2011.35.3.282     Document Type: Article

References (20)

1. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:193-205.
2. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83-8.
3. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-72.
4. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J (Clin Res Ed) 1984;288:1956-9.
5. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest 1985;45:589-97.
6. Kyllastinen M, Elfving S. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics. Gerontology 1986;32:317-26.
7. Nielsen NV, Tronier B. C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark. Diabetes Res 1986;3:475-8.
8. Keller U, Pasquel M, Berger W. C-peptide determination in diabetics for the evaluation of insulin requirements. Schweiz Med Wochenschr 1987;117:187-92.
9. Asano T, Kawamura M, Watanabe T, Abe M, Chin R, Miyazaki S, Hirata Y. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Japan Diabetes Soc 2008;51:759-63.
10. Ko GT, So WY, Tong PC, Chan WB, Yang X, Ma RC, Kong AP, Ozaki R, Yeung CY, Chow CC, Chan JC. Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 2009;180:919-26.
11. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T, Noda M. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 2010;57:237-44.
12. Shim WS, Kim SK, Kim HJ, Park SE, Kang ES, Rhee YM, Ahn CW, Lim SK, Kim KR, Lee HC, Cha BS. Clinical meaning of postprandial insulin secretory function in Korean type 2 diabetes mellitus. J Korean Diabetes Assoc 2005;29:367-77.
13. Kim RS, Yang IM, Kim JW, Kim YS, Kim KW, Kim SW, Choi YK. Postprandial 2-hr C-peptide concentration as a guide for insulin treatment in patient with NIDDM. Korean J Intern Med 1986;1:120-5.
14. Yoo HJ, Kim DM, Sung SK, Wee SO. Serum C-peptide concentration as an index of insulin treatment in NIDDM patients. J Korean Diabetes Assoc 1987;11:57-61.
15. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985;28:119-21.
16. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I, Binder C. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981;210:153-6.
17. Kim YK, Jeon JS, Lee JH, Ahn MA, Shong MH, Ro HK, Song CU, Yoon SI, Ku BJ. Practical clinical value of C-peptide test in the choice of insulin treatment in patients with noninsulin dependent diabetes mellitus. J Korean Diabetes Assoc 1995;19: 196-201.
18. Hue SH, Shin SH, Kim YS, Seo YK, Seol MJ, Oh YS. Practical value of glucagon test in the choice of treatment in diabetic patients. J Korean Diabetes Assoc 1985;11:63-9.
19. Park YS, Kim WB, Hong SK, Kim YS, Lee MK, Kim SY, Cho BY, Lee HK, Koh CS, Min HK, Rhee BD. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide in relation to clinical type of diabetes. J Korean Med Assoc 1991;34:655-65.
20. Pasquali R, Buratti P, Biso P, Patrono D, Capelli M, Pasqui F, Melchionda N. Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal. Diabete Metab 1987;13:44-51.